Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?

Insider Monkey12-12

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490931248?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06","is_english":true,"pubTime":"2024-12-12 00:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490931248","market":"us","top_or_hot":-1,"title":"Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?","media":"Insider Monkey","content":"<div>\n<p>We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-worst-164548389.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 00:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-worst-164548389.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-worst-164548389.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4210","symbol_name":"白银","start_time":0,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-worst-164548389.html","article_id":"2490931248","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490931248","pubTimestamp":1733935548,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG  stands against other worst ARK stocks to buy according to short sellers.Cathie Wood ofARK Investmentis one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world.At the heart of Ark Invest’s trading strategy is the fund’s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index’s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4210":"白银","LU1861558580.USD":"日兴方舟颠覆性创新基金B","AG":"First Majestic Silver Corporation","QLD":"纳指两倍做多ETF","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","SQQQ":"纳指三倍做空ETF","BK4544":"ARK ETF合集","CRSP":"CRISPR Therapeutics AG",".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","ARKK":"ARK Innovation ETF","TQQQ":"纳指三倍做多ETF","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4139":"生物科技","PSQ":"纳指反向ETF"},"translate_title":"卖空者认为CRISPR Therapeutics AG(CRSP)是最不值得购买的ARK股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AG":1,"CRSP":1,"ARKK":1,".IXIC":0.9,"MNQmain":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6},"content_text":"We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other worst ARK stocks to buy according to short sellers.\nCathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world.\nThis relentless focus on change means that if the economy is facing turbulence, then markets are not kind to Wood. To understand how: consider the cumulative value of her firm’s holdings as indicated by its 13F SEC filings. Starting from Q3 2020, analyzing the value for each subsequent year’s third quarter reveals how Ark Invest’s fortune fluctuates with economic winds. The hedge fund’s holdings were valued at $16.8 billion, $41.6 billion, $14.3 billion, and $13 billion during Q3 2020, Q3 2021, Q3 2022, and Q3 2023, respectively.\nThis shows that the value of Ark Invest’s holdings jumped by 148% between the third quarters of 2020 and 2021. Looking back to see why, market conditions back then were marked by easy liquidity, a surge in retail investing, and Wall Street’s bullishness for technology stocks. Technology and growth stocks are precisely the kinds that Wood invests in, and in the time period being analyzed, the shares of Elon Musk’s car company alone soared by 87%. Wood is one of the firm’s largest investors, and her patience has yielded results. Insider Monkey’s data shows that Ark Invest first bought the shares at an average price of $13.14 during Q4 2016. While it has grown its holdings from the 274,725 shares held back then to 4.6 million shares as of Q3 2024, even if Wood hadn’t bought additional shares, her original holdings would currently be worth $62.7 million right now for a remarkable 1,508% gain!\nYet, while Musk’s company is Wood’s greatest hit, there have been misses as well since the idea of investing in disruptive innovation carries the unavoidable pitfall of targeting some firms that fail to deliver on lofty ideas. We analyzed the share price performance of some of her longest-held stocks as part of our coverage of 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. At the time the list was published, its three worst-performing stocks were down by 81.85%, 95.11%, and 99% since 2020 end. Extrapolating their performance to December 2024, the first two stocks, which rank 2nd and 4th have lost 75% and 94.5%.\nAt the heart of Ark Invest’s trading strategy is the fund’s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index’s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%.\nWood’s ETF’s performance can also be divided into pre and post-election gains. Before the election, it was down 7.6% year-to-date after having bled 13% during H1 2024. As H1 ended, Wood acknowledged the troubling time her firm was facing in an investor letter. She admitted “fully that the macro environment and some stock picks have challenged our recent performance” but went on to add that her firm’s “conviction in and commitment to investing in disruptive innovation have not wavered.” According to Wood, Ark had to remain persistent back then since exiting our strategies now would crystallize losses that lower interest rates and reversions to the mean should transform into meaningful profits during the next few years.”\nThe mean reversion she is referring to is the differential in the performance between the Russel Value and Growth stock indexes in the infamous dot-com bubble. Wood pointed out that “At its worst in 2000, the Russell Value Index underperformed the Russell Growth Index by more ~3,500 basis points on a year-over-year basis but, within roughly one year, the relative performance flipped and reached a positive ~4,800 basis points, more than an 80-percentage point swing, as shown below.” She believes that Ark’s strategy to diversify away from the Magnificent 6 (Magnificent 7 ex Tesla) through “increased exposure to multiomics stocks that have been hit hardest by “higher for longer” interest rates” led to disappointing performance.\nThe potential upside from this diversification was evident in 2023 as the flagship fund “appreciated 68% as the bull market started to broaden out based on just the “whiff” of lower interest rates, despite its diversification away from the Magnificent Six and toward what we believe are more disruptive names,” according to Wood. To wit, while the flagship fund was down 7.6% YTD before the election after the ballots were cast and counted, it has gained 26% to bring its YTD performance to 20.46%. The benchmark S&P index, on the other hand, is up by 28.3%.\nOur Methodology\nFor our list of the worst Ark stocks to buy according to short sellers, we ranked the 110 largest holdings in Ark Invest’s Q3 2024 SEC filings by the percentage of shares outstanding that were sold short and selected the stocks with the highest percentage.\nFor these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A laboratory cultivating cells for the development of gene and cell therapies. \nCRISPR Therapeutics AG (NASDAQ:CRSP)\nShort Interest as % of  Shares Outstanding: 22.72%\nNumber of Hedge Fund Investors In Q3 2024: 27\nArk Invest’s Q3 2024 Stake: $352 million\nCRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most important firms in the genomic industry. The firm’s CRISPR gene sequencing platform is nearly synonymous with the technology itself. Since CRISPR Therapeutics AG (NASDAQ:CRSP)’s products are used to manufacture medicines that rely on gene sequencing, the firm is dependent on the health of gene-based medicine for its revenue. This dependence is particularly pronounced since CRISPR Therapeutics AG (NASDAQ:CRSP) lacks diversification to pivot away to other sectors. Fortunately for the firm, its partnership with Vertex has led to the first sickle cell gene therapy treatment called CASGEVY. The treatment has also been approved in Canada and Switzerland, and CRISPR Therapeutics AG (NASDAQ:CRSP) is also developing medicines to treat lymphoma and tumors. These are in Phase 1 development, so over the short term, CASGEVY’s market performance and payments to CRISPR Therapeutics AG (NASDAQ:CRSP) will drive the hypothesis.\nOverall, CRSP ranks 1st on our list of worst ARK stocks to buy according to short sellers. CRSP is a Cathie Wood stock that short sellers love. While we acknowledge the potential of CRSP as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock\nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490931248"}